Target intelligence / Profile preview

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (NDUFA9)

Target
NDUFA9
Molecular classification
Enzyme, Electron transport chain complex subunit, Mitochondrial complex I accessory subunit
01

Overview

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (NDUFA9) is an accessory subunit of Complex I (NADH:ubiquinone oxidoreductase) in the mitochondrial inner membrane[1][2][3][5]. Complex I is responsible for transferring electrons from NADH to ubiquinone (coenzyme Q), driving proton translocation and ATP production during oxidative phosphorylation[1][2][3][5]. NDUFA9 is crucial for proper assembly of Complex I but is not directly involved in catalysis; instead, it contributes to the structural stability of the enzyme complex[2][5]. Mutations or altered expression of NDUFA9 have been associated with severe mitochondrial disorders such as Leigh syndrome and mitochondrial complex I deficiency, presenting mainly with neurological symptoms[1][2]. Drugs such as rotenone and metformin can interact with the overall Complex I, impacting functions in which NDUFA9 is critical[5].

Other names
NDUFA9CI-39kCI-39kDComplex I-39kDCOQ11SDR22E1NDUFS2LMC1DN26Short chain dehydrogenase/reductase family 22E, member 1NADH:ubiquinone oxidoreductase subunit A9
02

Mechanism of action

Inhibition of electron transfer via Complex I (inhibitors such as rotenone block the NDUFA9-containing complex, reducing ATP synthesis and increasing reactive oxygen species generation). Modulation of mitochondrial oxidative phosphorylation (e.g., by metformin).

03

Biological functions

Electron transfer from NADH to ubiquinone (coenzyme Q)Cellular energy production (ATP synthesis via oxidative phosphorylation)Assembly and stabilization of Complex I in the mitochondrial respiratory chain
04

Disease associations

Neurodegenerative disease (e.g., Leigh syndrome)Mitochondrial Complex I deficiencyLeukodystrophy
05

Safety considerations

Neurotoxicity and lactic acidosis (risk in drugs inhibiting or modulating Complex I function)Mitochondrial toxicity leading to muscle or nerve damageIncreased reactive oxygen species and oxidative stress upon inhibition
06

Interacting drugs

Rotenone (Complex I inhibitor)

3 more in the full profile.

07

Biomarkers

Reduced NDUFA9 expression or Complex I activity in fibroblasts as a marker for mitochondrial diseaseMitochondrial respiratory chain enzyme assays used in clinical diagnostic settings

Beyond the preview

Go deeper on NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (NDUFA9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (NDUFA9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call